Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
4.220
+0.080 (1.93%)
Oct 8, 2026, 1:20 PM EDT - Market open
Verrica Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 30.32 | 35.58 | 7.57 | 5.12 | 9.03 | 12 | |
Revenue Growth | 106.21% | 370.22% | 47.66% | -43.27% | -24.73% | - |
Cost of Revenue | 18.9 | 12.3 | 14.58 | 21.04 | 12.92 | 15.93 |
Gross Profit | 11.43 | 23.28 | -7.01 | -15.92 | -3.89 | -3.93 |
Selling, General & Admin | 37.86 | 35.22 | 58.82 | 47.31 | 17.41 | 26.98 |
Operating Expenses | 37.86 | 35.22 | 58.82 | 47.31 | 17.41 | 26.98 |
Operating Income | -26.43 | -11.94 | -65.84 | -63.22 | -21.3 | -30.91 |
Interest Expense | -3.73 | -7.74 | -9.41 | -3.96 | -2.17 | -4.3 |
Interest & Investment Income | 0.68 | 0.93 | 1.42 | 2.74 | 0.48 | 0.12 |
Other Non Operating Income (Expenses) | 1.78 | 2.65 | -2.67 | -0.01 | -0.06 | - |
EBT Excluding Unusual Items | -27.71 | -16.11 | -76.5 | -64.46 | -23.05 | -35.08 |
Gain (Loss) on Sale of Assets | -0.25 | -0.25 | -0.08 | -2.54 | - | - |
Other Unusual Items | -1.53 | -1.53 | - | - | -1.44 | - |
Pretax Income | -31.18 | -17.89 | -76.58 | -67 | -24.49 | -35.08 |
Earnings From Continuing Operations | - | -17.89 | -76.58 | -67 | -24.49 | -35.08 |
Net Income | -31.18 | -17.89 | -76.58 | -67 | -24.49 | -35.08 |
Net Income to Common | -31.18 | -17.89 | -76.58 | -67 | -24.49 | -35.08 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 17 | 11 | 5 | 5 | 3 | 3 |
Shares Outstanding (Diluted) | 17 | 11 | 5 | 5 | 3 | 3 |
Shares Change | 117.95% | 105.61% | 14.26% | 32.72% | 26.32% | 8.20% |
EPS (Basic) | -1.88 | -1.68 | -14.78 | -14.78 | -7.17 | -12.97 |
EPS (Diluted) | -1.88 | -1.68 | -14.78 | -14.78 | -7.17 | -13.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -13.35 | -17.63 | -60.95 | -38.94 | -18.95 | -28.47 |
Free Cash Flow Per Share | -0.81 | -1.66 | -11.77 | -8.59 | -5.55 | -10.53 |
Gross Margin | 37.68% | 65.44% | -92.70% | - | -43.08% | -32.74% |
Operating Margin | -87.18% | -33.56% | -870.16% | -1233.84% | -235.78% | -257.57% |
Profit Margin | -102.84% | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% |
Free Cash Flow Margin | -44.02% | -49.55% | -805.63% | -759.93% | -209.83% | -237.21% |
EBITDA | -25.96 | -11.45 | -64.88 | -62.67 | -20.84 | -30.66 |
EBITDA Margin | -85.63% | -32.20% | - | - | -230.76% | -255.53% |
D&A For EBITDA | 0.47 | 0.49 | 0.96 | 0.55 | 0.45 | 0.24 |
EBIT | -26.43 | -11.94 | -65.84 | -63.22 | -21.3 | -30.91 |
EBIT Margin | -87.18% | -33.56% | - | - | -235.78% | -257.57% |
Revenue as Reported | 30.32 | 35.58 | 7.57 | 5.12 | 9.03 | - |